Switzerland's Galderma raised its full-year guidance on Thursday after third-quarter sales beat expectations despite pressure from US tariffs, sending shares in the skincare company up around 7%.

Third-quarter net sales came in at $1.29 billion compared with the $1.24 billion provided in a company-compiled consensus.

Galderma, which listed in March 2024, now expects full-year net sales to increase by between 17% and 17.7% year-on-year at constant currency, up from 12% to 14% previously.

The firm highlighted strong growth in its Nemluvio dermatology portfolio and said it has committed to spend more than $650 million on US manufacturing through 2030.

"We've overall shifted a lot of focus to the US also because the growth is incredibly strong in the US," CEO Flemming Ornskov told Reuters.

See Full Page